evolocumab
evolocumab: 9 clinical trials tracked.
evolocumab evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about evolocumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 2 study sponsors
Clinical Trial Registry Records (9)
A Phase 4, Open-label, Blinded Primary Endpoint, Randomized Multicenter Trial to Assess the Effectiveness of Evolocumab With Routine Lipid Management Compared With Routine Lipid Management Alone in Reducing the Plaque Burden in Patients With Subclinical Atheroma
Primary endpoint: Change in Non-Calcified Plaque (NCP) Volume from Baseline to Week 72
A Randomized, Placebo-Controlled Mechanistic Clinical Trial of PCSK9 Inhibition With Evolocumab in Patients Undergoing Open Abdominal Aortic Aneurysm Repair
Primary endpoint: Interleukin (IL)-6 in myeloid derived monocytes/macrophages from in AAA tissue
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Primary endpoint: Safety and adverse events (AEs)
Acute Myocardial Infarction Upbound to PCI Immediately (STEMI) or in the Next Three Days (NSTEMI), and Randomized to Subcutaneous Evolocumab or Normal Strategies to Reach Guidelines LDL Objectives in the Real-world - The AMUNDSEN-real Study
Primary endpoint: LDL-C reduction of ≥ 50% from baseline and a final LDL-C of <1.4 mmol/L (<55 mg/dL) at 12 months follow-up
Dose Response and Safety of an Oral PCSK9i, NNC0385-0434, in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk on Maximally Tolerated Statin Dose and Other Lipid-lowering Therapy Requiring Further LDL-C Reduction
Primary endpoint: Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol
Lipid Management in Renal Transplant Recipients: a Pilot Study Evaluating the Use of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) Inhibitor Evolocumab.
Primary endpoint: Percent Change in LDL Cholesterol From Baseline to 12 Months
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Primary endpoint: Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First
The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)
Primary endpoint: Number of Adverse Events
Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study
Primary endpoint: Percent Change in LDL-Cholesterol